These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29941528)

  • 1. FDA approves nonopioid medication for managing opioid withdrawal.
    Traynor K
    Am J Health Syst Pharm; 2018 Jul; 75(13):927. PubMed ID: 29941528
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 3. Lofexidine (Lucemyra) for opioid withdrawal.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):115-117. PubMed ID: 30036346
    [No Abstract]   [Full Text] [Related]  

  • 4. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 5. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
    Doughty B; Morgenson D; Brooks T
    Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [α2-Agonists during withdrawal].
    Tonner PH; Paris A
    Pharm Unserer Zeit; 2011 Nov; 40(6):481-2. PubMed ID: 22028132
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convincing effects of clonidine on neurohumoral withdrawal symptoms during antagonist-supported detoxification of opioid addicts.
    White PF; Wender RH
    Anesth Analg; 2003 Nov; 97(5):1548. PubMed ID: 14570693
    [No Abstract]   [Full Text] [Related]  

  • 9. Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms.
    Bryce C
    Am Fam Physician; 2019 Mar; 99(6):392-394. PubMed ID: 30874408
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction of opiate withdrawal symptoms with use of clonidine in a county jail.
    Fresquez-Chavez KR; Fogger S
    J Correct Health Care; 2015 Jan; 21(1):27-34. PubMed ID: 25431436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New directions in the treatment of opioid withdrawal.
    Srivastava AB; Mariani JJ; Levin FR
    Lancet; 2020 Jun; 395(10241):1938-1948. PubMed ID: 32563380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
    Gish EC; Miller JL; Honey BL; Johnson PN
    Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detoxification and treating opioid dependence.
    de Jong CJ
    JAMA; 2006 Feb; 295(8):887; author reply 887-8. PubMed ID: 16493098
    [No Abstract]   [Full Text] [Related]  

  • 14. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
    Kuszmaul AK; Palmer EC; Frederick EK
    J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conflicting information from TGA versus FDA may undermine compliance with use of medication.
    Beckmann KM
    Med J Aust; 2013 Jul; 199(1):28-9. PubMed ID: 23829255
    [No Abstract]   [Full Text] [Related]  

  • 18. Case Report: Concurrent Clonidine Abuse and Opioid Use Disorder.
    Mitchell BG; Lee J
    J Psychoactive Drugs; 2021; 53(4):373-377. PubMed ID: 33814003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emperor' s new clothes.
    Schnoll SH
    J Addict Dis; 2003; 22(4):1-4. PubMed ID: 14723473
    [No Abstract]   [Full Text] [Related]  

  • 20. Lofexidine based regimen for opiate addicts.
    Wylie AS; Stewart AM
    Br J Gen Pract; 1995 Apr; 45(393):217-8. PubMed ID: 7612327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.